Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M31.9Revenue (TTM) $M0.3Net Margin (%)-2,970.9Altman Z-Score10.5
Enterprise Value $M6.7EPS (TTM) $-0.5Operating Margin %-3,050.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score0.7Pre-tax Margin (%)-2,993.8Higher ROA y-yY
Price/Book1.110-y EBITDA Growth Rate %-25.3Quick Ratio23.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %1.1Current Ratio23.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-29.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-30.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M19.3ROIC % (ttm)-922.3Gross Margin Increase y-yN

Gurus Latest Trades with NVGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NVGN is held by these investors:



NVGN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVGN:

    News about NVGN:

    Articles On GuruFocus.com
    Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 

    More From Other Websites
    Appendix 3B New Nov 22 2016
    Change in Director's Interest New Nov 07 2016
    NOVOGEN LTD Financials Nov 03 2016
    Change in Director's Interest New Nov 03 2016
    Change in Director's Interest New Nov 01 2016
    Conversion of convertible notes and issue of Options New Nov 01 2016
    In-licensing of GDC-0084 – Investor Presentation New Nov 01 2016
    Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in... Oct 30 2016
    Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma Oct 30 2016
    Appendix 3B and Cleansing Notice New Oct 30 2016
    In-licensing of GDC-0084 New Oct 30 2016
    Novogen Licenses Phase II-ready Molecule from Genentech for Development in Glioblastoma for $5M... Oct 30 2016
    Novogen Acquires Privately-held Glioblast for AU$2.1M in Cash, Stock, Plus Milestones Oct 30 2016
    In-licensing of GDC-0084 New Oct 30 2016
    Accompanying Investor Presentation New Oct 30 2016
    Acquisition of Glioblast New Oct 30 2016
    SEC Form 20F New Oct 28 2016
    Appendix 4G and Corporate Governance Statement New Oct 25 2016
    Issue of unlisted options under ESOP New Oct 20 2016
    Annual Report for the year ended 30 June 2016 New Oct 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)